Press Releases Werewolf Therapeutics, Inc.

Equities

HOWL

US95075A1079

Market Closed - Nasdaq Other stock markets 01:30:00 17/05/2024 am IST			5-day change	1st Jan Change
4.88 ^USD	+0.62%		-12.39%	+26.42%

03/05	Werewolf Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
23/04	Werewolf Therapeutics, Inc. Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease at AAI Annual Meeting	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Werewolf Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update	03/05	AQ
Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting	24/04	AQ
Werewolf Therapeutics Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease (IBD) at AAI Annual Meeting	23/04	AQ
Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics WTX-518 and WTX-712 at AACR 2024 Annual Meeting	06/04	AQ
Werewolf Therapeutics to Present First-of-Its-Kind Data Demonstrating Utility for PREDATOR™ Platform in Immunology-Based Diseases at AAI Annual Meeting	05/04	AQ
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	07/03	AQ
Werewolf Therapeutics to Present at the 2024 Leerink Partners Global Biopharma Conference	06/03	AQ
Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2024	06/03	AQ
Werewolf Therapeutics Provides Business Update and Highlights 2024 Strategic Outlook	08/01	AQ
Werewolf Therapeutics Appoints Michael Atkins, M.D., to its Board of Directors	05/01	AQ
Werewolf Therapeutics to Present at the Evercore ISI HealthCONx Conference	22/11	AQ
Werewolf Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update	15/11	AQ
Werewolf Therapeutics Presents Preliminary Monotherapy Data from Phase 1/1b Clinical Trial Establishing Proof of Mechanism for WTX-124 at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting	03/11	AQ
Werewolf Therapeutics to Present Clinical and Preclinical Data at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting	31/23/31	AQ
Werewolf Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting	27/23/27	AQ
Werewolf Therapeutics to Host KOL Event Highlighting IL-2 Landscape and Opportunity for WTX-124	12/23/12	AQ
Werewolf Therapeutics to Participate in Upcoming Investor Conferences	06/23/06	AQ
Werewolf Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update	10/23/10	AQ
Werewolf Therapeutics to Present at the Jefferies Healthcare Conference	01/23/01	AQ
WEREWOLF THERAPEUTICS, INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K)	11/23/11	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Werewolf Therapeutics, Inc.

Equities

HOWL

US95075A1079

Press Releases

Filters